BioSpace News Archive

According to recent surveys, nearly 50% of Americans say they are unlikely to get a COVID-19 vaccine when it becomes available. The main reasons cited are concerns about potential negative side effects and a lack of trust and transparency in the approval process

This is the company’s 6th FDA clearance and further solidifies its leadership as the most comprehensive acute AI vendor in the market

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has signed an agreement with a leading clinical quality and validation processes consultancy to oversee the preparation and submissi

NephCure Kidney International and Retrophin, in partnership with the American Association of Kidney Patients (AAKP), today released an expert paper with policy recommendations to coincide with American So

Series of Scientific Publications Demonstrate up to 99% Reduction of Airborne Respiratory Droplets Including Those not Captured by Surgical Masks Commercial Launch Provides Immediate, Broad Availability with Pulmatrix to Receive Escalating Royalties on Product Sales

Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) on the effectiveness of an MF59 ® -adjuvanted, trivalent seasonal influenza vaccine (aTIV) in adults 65 years and older during the 2018/19 U.S. influenza season at the IDWeek 2020 virtual conference. 1 aTIV was found to be more effecti

Medly partners with EmblemHealth and the New York City Housing Authority to provide underserved communities in the Brooklyn area access to the influenza vaccination

Represents largest dd-cfDNA retransplant study to date and demonstrates clinical value of proprietary background cfDNA technology

BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in Omaha to collect standard plasma from healthy donors.

Ferring and Rebiotix, a Ferring Company, will present two oral abstracts describing translational studies of investigational microbiome-based therapeutics RBX2660 and RBX7455 for the treatment of recurrent Clostridioides difficile (C. diff) infection These data presentations strengthen the company’s leadership and scientific and clinical understanding of the two investigational therapeutics